Norwegian screening program reduces breast cancer-related death rates
the ONA take:
A Norwegian breast cancer screening program has markedly reduced breast cancer mortality, according to an evaluation of the pilot project.
As part of the Norwegian Breast Cancer Screening Programme, all women aged 50 to 69 are invited to undergo a mammography screening every 2 years. When the program was launched in 1995, only women in four Norwegian counties were invited to participate, but in 2004, the project went national.
The evaluation showed that the screening program reduced breast cancer mortality by up to 20 to 30% in women aged 50 to 69 who have been followed up until age 79. The goal of the program was to reduce breast cancer-related death by 30%.
The researchers estimate that for every 100,000 women invited to participate in the program, approximately 377 cases of tumors or pre-malignant breast lesions will be identified. Of those, about 27 will avoid breast cancer-related death due to early diagnosis and treatment.
The downside of the program is that approximately 142 per 100,000 women will be overdiagnosed with breast cancer.
A Norwegian breast cancer screening program has markedly reduced breast cancer mortality.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|